Loading cancer entity…
Loading cancer entity…
Clinical trials
10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,641)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03331341 | Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07102706 | Phase I Trial of GR1803 Injection in Patients With RRMM | completed | Phase 1 / Phase 2 | 76 | Genrix (Shanghai) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 5, 2025 | clinicaltrials |
| NCT01711671 | A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 8 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT03013218 | A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) | completed | Phase 1 | 174 | ALX Oncology Inc.INDUSTRY | 2 | Aug 1, 2025 | clinicaltrials |
| NCT03548207 | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma(CARTITUDE-1) | completed | Phase 1 / Phase 2 | 126 | Janssen Research & Development, LLCINDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT01864018 | Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis | completed | Phase 1 / Phase 2 | 87 | Mayo ClinicOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT04813653 | Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells | completed | Phase 1 | 3 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jul 24, 2025 | clinicaltrials |
| NCT04473911 | Haplo Peripheral Blood Sct In GVHD Prevention | completed | Phase 1 | 25 | Zachariah Michael DeFilippOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05011097 | A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 20 | Wuhan YZY Biopharma Co., Ltd.INDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT02956382 | Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma | completed | Phase 1 / Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT01051635 | A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2025 | clinicaltrials |
| NCT03884556 | TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers | completed | Phase 1 | 56 | Trishula Therapeutics, Inc.INDUSTRY | 1 | Jul 2, 2025 | clinicaltrials |
| NCT02546167 | CART-BCMA Cells for Multiple Myeloma | completed | Phase 1 | 25 | University of PennsylvaniaOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT01995669 | Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT03900598 | A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 226 | Janssen Research & Development, LLCINDUSTRY | 12 | Jun 22, 2025 | clinicaltrials |
| NCT03770260 | Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment | completed | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 19, 2025 | clinicaltrials |
| NCT03742258 | Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma | completed | Phase 1 | 12 | Northwestern UniversityOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT02303392 | Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma | completed | Phase 1 | 34 | Jennifer WoyachOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT00112827 | Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma | completed | Phase 1 / Phase 2 | 54 | City of Hope Medical CenterOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05290155 | Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies | completed | Phase 1 | 14 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05567601 | Doxil/Caelyx BE Study | completed | Phase 1 | 36 | Baxter Healthcare CorporationINDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT03448393 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies | completed | Phase 1 | 54 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03870945 | Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) | completed | Phase 1 | 12 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT04696432 | A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma | completed | Phase 1 | 7 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT02519452 | A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 120 | Janssen Research & Development, LLCINDUSTRY | 6 | May 23, 2025 | clinicaltrials |
| NCT04317885 | A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects | completed | Phase 1 | 25 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04655677 | A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma | completed | Phase 1 | 10 | Peking Union Medical College HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04240808 | Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) | completed | Phase 1 | 10 | University of Colorado, DenverOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT02580539 | A Study of the Safety and Efficacy of EBV Specific T-cell Lines(EBV-TCL-01) | completed | Phase 1 / Phase 2 | 12 | Dr. Jean-Sebastien Delisle, MD, PhDOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT03583424 | Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 19 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT03417284 | Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT01458366 | Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide | completed | Phase 1 / Phase 2 | 38 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT01998971 | A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma | completed | Phase 1 | 240 | Janssen Research & Development, LLCINDUSTRY | 3 | Apr 25, 2025 | clinicaltrials |
| NCT03939182 | Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma | completed | Phase 1 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT04578600 | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | completed | Phase 1 | 8 | Joseph TuscanoOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT04836195 | Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma | completed | Phase 1 | 29 | Pacylex PharmaceuticalsINDUSTRY | 1 | Apr 17, 2025 | clinicaltrials |
| NCT00511082 | Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | completed | Phase 1 | 7 | Otsuka Beijing Research InstituteINDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT05190068 | HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 89 | HutchmedINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT03755414 | Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation | completed | Phase 1 | 55 | Washington University School of MedicineOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT02616965 | A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma | completed | Phase 1 | 16 | Fox Chase Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04758767 | CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 10 | CASI pharmaceuticals, Inc.INDUSTRY | 2 | Apr 3, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT01877382 | A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 107 | Daiichi SankyoINDUSTRY | 1 | Mar 27, 2025 | clinicaltrials |
| NCT06892119 | Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation | completed | Phase 1 | 6 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT01163357 | Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma | completed | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT03792256 | Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) | completed | Phase 1 | 12 | Children's Oncology GroupNETWORK | 1 | Mar 21, 2025 | clinicaltrials |
| NCT01476839 | Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT01758328 | Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT02342782 | Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma | completed | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 5, 2025source: clinicaltrials